HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma  by Gordan, John D. et al.
Cancer Cell
ArticleHIF-a Effects on c-Myc Distinguish
Two Subtypes of Sporadic VHL-Deficient
Clear Cell Renal Carcinoma
John D. Gordan,1,2 Priti Lal,3 Vijay R. Dondeti,1,2 Richard Letrero,2,4 Krishna N. Parekh,1,2,5 C. Elisa Oquendo,2,4
Roger A. Greenberg,1,2 Keith T. Flaherty,2,4 W. Kimryn Rathmell,6 Brian Keith,1 M. Celeste Simon,1,2,5,*
and Katherine L. Nathanson2,4
1Abramson Family Cancer Research Institute
2Abramson Cancer Center
3Department of Pathology
4Department of Medicine
5Howard Hughes Medical Institute
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
6Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*Correspondence: celeste2@mail.med.upenn.edu
DOI 10.1016/j.ccr.2008.10.016SUMMARY
von Hippel-Lindau (VHL) tumor suppressor loss results in hypoxia-inducible factor alpha (HIF-a) stabilization
and occurs in 70% of sporadic clear cell renal carcinomas (ccRCCs). To determine whether opposing influ-
ences of HIF-1a and HIF-2a on c-Myc activity regulate human ccRCC progression, we analyzed VHL geno-
type and HIF-a expression in 160 primary tumors, which segregated into three groups with distinct molecular
characteristics. Interestingly, ccRCCs with intact VHL, as well as pVHL-deficient HIF-1a/HIF-2a-expressing
ccRCCs, exhibited enhanced Akt/mTOR and ERK/MAPK signaling. In contrast, pVHL-deficient ccRCCs
expressing only HIF-2a displayed elevated c-Myc activity, resulting in enhanced proliferation and resistance
to replication stress. These reproducible distinctions in ccRCC behavior delineate HIF-a effects on c-Myc
in vivo and suggest molecular criteria for selecting targeted therapies.INTRODUCTION
Mutation or silencing of the von Hippel-Lindau (VHL) tumor sup-
pressor gene occurs in a majority of inherited and sporadic clear
cell renal carcinomas (ccRCCs) (Banks et al., 2006; Kim and
Kaelin, 2004; Kondo et al., 2002b; Lonser et al., 2003). VHL en-
codes pVHL, a critical regulator of the hypoxia-inducible factor
(HIF) transcriptional activators (Kim and Kaelin, 2004). HIFs are
heterodimeric basic helix-loop-helix/PAS proteins consisting of
an a subunit (HIF-1a or HIF-2a) and a b subunit (HIF-1b or
ARNT [aryl hydrocarbon receptor nuclear translocator]). HIFs
mediate cellular adaptation to low O2 by activating the transcrip-Ction of target genes involved in metabolism, angiogenesis, and
extracellular matrix (ECM) remodeling (Gordan and Simon,
2007; Pugh and Ratcliffe, 2003). pVHL is part of the recognition
component of a ubiquitin ligase complex that targets HIF-a sub-
units for normoxic degradation, a process that is inhibited under
hypoxic conditions (typically <5% O2) by several mechanisms.
Although pVHL has additional molecular functions affecting
fibronectin assembly (Kim and Kaelin, 2004), microtubule stabil-
ity (Hergovich et al., 2003), and atypical protein kinase C activity
(Lee et al., 2005), results from ccRCC xenograft experiments
indicate that HIF-a regulation is critical for VHL tumor suppressor
function.SIGNIFICANCE
Constitutive hypoxia-inducible factor (HIF) activity is clearly associated with clear cell renal carcinoma (ccRCC) tumorigen-
esis; however, the influence of individual HIF-a subunits on cell growth mechanisms in vivo is unknown. Few dominant
oncogenic pathways have been identified within ccRCC, making it difficult to select optimal targeted therapies for patients
or to predict disease outcome except by grade and stage. Cell culture experiments indicate that HIF-1a inhibits the c-Myc
oncoprotein, whereas HIF-2a potentiates c-Myc transcriptional activity and cellular proliferation. The findings reported here
indicate that HIF-1a and HIF-2a promote distinct oncogene activation in human ccRCCs and reveal a critical role for HIF-2a
and c-Myc in promoting genomic integrity. These results suggest that evaluating pVHL status and HIF-a expressionmay aid
targeted therapy selection for human ccRCCs.ancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc. 435
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HIF-2a/Myc Effects on RCC BehaviorHIF-1a and HIF-2a have overlapping effects on aspects of an-
giogenesis and ECM remodeling; however, they also exhibit dis-
tinct effects on cell metabolism and proliferation (Gordan et al.,
2007b). For example, HIF-1a is uniquely able to stimulate glyco-
lytic enzyme expression (Hu et al., 2003; Wang et al., 2005) while
blocking anabolic biosynthesis by limiting mitochondrial pyru-
vate consumption (Kim et al., 2006; Lum et al., 2007; Papan-
dreou et al., 2006). HIF-1a also opposes cell-cycle progression
in vitro by posttranslationally inhibiting the c-Myc oncoprotein
(Koshiji et al., 2004). In direct contrast, HIF-2a does not regulate
glycolytic gene expression (Hu et al., 2003) but uniquely stimu-
lates expression of the stem cell factor Oct-4 (Covello et al.,
2006) and promotes cell-cycle progression by enhancing
c-Myc-mediated activation of cyclin D2 and E2F1 and repres-
sion of p21 and p27 (Gordan et al., 2007a). Intriguingly, indepen-
dent reports have demonstrated that the HIF-2a subunit is pri-
marily responsible for the growth of pVHL-deficient human
ccRCC xenografts (Kondo et al., 2002a, 2003; Maranchie
et al., 2002). Moreover, in VHL disease, the cancer-susceptibility
syndrome associated with germline VHL mutation, HIF-1a ex-
pression gradually decreases whereas HIF-2a expression in-
creases as ccRCCs develop (Mandriota et al., 2002; Raval
et al., 2005). The differential effects of HIF-1a and HIF-2a on
c-Myc provide an appealing mechanistic explanation for the ac-
tivity of HIF-2a in VHL disease-associated ccRCC (Mandriota
et al., 2002; Raval et al., 2005). However, no studies have directly
assessed the differential effects of HIF-1a and HIF-2a on c-Myc
or other oncogenic pathways in human ccRCC.
In addition to driving cellular proliferation, oncogenes can also
contribute to genomic instability by disrupting cell-cycle con-
trols and cellular metabolism (Halazonetis et al., 2008). Cell-
cycle checkpoint inactivation allows DNA replication in aneu-
ploid cells and may favor oncogenic genomic amplifications
by repetitively triggering replication origins during a single
S phase (Hook et al., 2007). Furthermore, many oncogenes alter
cellular metabolism, leading to the production of reactive oxy-
gen species that directly modify DNA (Lee et al., 1999). Both pro-
cesses result in disrupted chromosomal structures and replica-
tion fork stalling or collapse, triggering a cell-intrinsic DNA
damage response (Bartkova et al., 2005; Gorgoulis et al.,
2005). In low-stage tumors, this damage causes a G0-like phe-
notype following incomplete DNA replication (Bartkova et al.,
2006; Di Micco et al., 2006), while its impact on more advanced
tumors is less clear. High levels of c-Myc overexpression can re-
sult in accumulation of significant DNA damage (Ray et al., 2006;
Vafa et al., 2002). In contrast, intermediate c-Myc expression
levels may actually promote genomic stability, consistent with
the observation that DNA damage is reduced when c-Myc is in-
hibited by HIF-1a (Huang et al., 2007; Koshiji et al., 2005). There-
fore, we also examined the possibility that activation of c-Myc by
HIF-2a might enhance genomic stability in low-stage ccRCCs,
thus enhancing tumor cell proliferation by limiting DNA damage
checkpoint activation.
In this report, we describe the characterization of more than
160 sporadic human ccRCC tumor samples based onVHL geno-
type and HIF-a expression patterns. Our initial investigations
identified three distinct ccRCC groups: (1) tumors with wild-
type VHL alleles and undetectable HIF-a protein expression
(designated ‘‘VHLWT’’), (2) VHL-deficient tumors expressing de-436 Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inctectable HIF-1a and HIF-2a proteins (designated ‘‘H1H2’’), and
(3) VHL-deficient tumors expressing HIF-2a exclusively (desig-
nated ‘‘H2’’). VHL WT, H1H2, and H2 tumors were extensively
characterized for differences in cell proliferation, patterns of on-
cogene activation, and genomic integrity. These analyses were
extended to include two independent renal cancer sample sets
and HIF-1a- or HIF-2a-deficient tumor cell lines. We wished to
determine whether human ccRCCs can be subclassified into
distinct groups based on VHL status and HIF-a expression pat-
terns, which in turn correspond to the activation of distinct onco-
genic signaling and DNA repair pathways. The overall objective
of these studies is to ultimately provide a strategy to stratify
patients for targeted therapies.
RESULTS
Identifying Three Groups of ccRCC
We determined the HIF-a expression patterns and VHL status of
57 independent sporadic human ccRCCs obtained from the Col-
laborative Human Tissue Network (CHTN). HIF immunostaining
patterns separated the tumors into three distinct groups: no
HIF-a protein detected (‘‘VHL WT,’’ 12%), both HIF-1a and
HIF-2a detected (‘‘H1H2,’’ 61%), or HIF-2a detected exclusively
(‘‘H2,’’ 27%). Classification was based on HIF-a expression
solely in tumor cells. Interestingly, none of the sporadic tumors
we evaluated expressed only HIF-1a, strongly suggesting that
HIF-2a is critical for development of pVHL-deficient human
ccRCCs. HIF-a protein staining in H1H2 and H2 specimens
was predominantly nuclear and appeared in >75% of tumor
cells, whereas VHL WT tumors exhibited HIF-a staining in <5%
of nuclei (Figure 1A). VHL sequencing, copy number, and meth-
ylation analysis confirmed that all HIF-a-negative tumors (7 of 7)
had wild-type VHL alleles, whereas all but one of the HIF-a-pos-
itive tumors (49 of 50) harbored biallelic VHL inactivation by mu-
tation, deletion, or methylation (Figure 1B; see also Table S1
available online). Most tumors displayed single-allele point or
frameshift VHL mutations, accompanied by deletion of the re-
maining allele. The spectrum and relative frequencies of VHL
mutations were consistent with published analyses of sporadic
ccRCC (Banks et al., 2006; Kondo et al., 2002b). Similar to pre-
vious observations (Banks et al., 2006; Kondo et al., 2002b), we
found two tumors with one deleted and one intact VHL allele; of
these, one tumor had no HIF-a staining and was classified as
VHL WT, whereas the other exhibited faint but distinct HIF-2a
staining and was excluded from further analysis.
Multiple controls were performed to substantiate the immuno-
histochemistry (IHC) and genotyping. Asmeasured by qRT-PCR,
VHL mRNA levels were reduced to <50% and <20% of normal
renal epithelium in VHL mutant tumors and VHL-methylated
tumors, respectively (data not shown). HIF-a protein was mea-
sured by western blot assays, and protein levels in the three sub-
groups were consistent with IHC results. Immunoblots showed
low levels of HIF-1a expression in H2 tumors (<10% of the level
in H1H2 tumors), which likely reflects HIF-1a protein in endothe-
lial cells (Figure S1). By comparing tumor protein extracts to
known quantities of epitope-tagged HIF-a protein, we deter-
mined that HIF-1a and HIF-2a were expressed at essentially
equivalent levels in H1H2 tumors (Figure S1 and data not shown).
There was no clear difference in HIF-1a mRNA levels between.
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HIF-2a/Myc Effects on RCC BehaviorFigure 1. Categorization of Clear Cell Renal
Carcinomas by HIF-a Expression and VHL
Status
(A) Representative HIF-1a and HIF-2a staining of
fresh-frozen tumors categorized as VHL WT,
H1H2, or H2. Scale bar = 1 mm.
(B) Summary of VHL disruption in H1H2 and H2
tumors. Mutations are separated into those occur-
ring in the first two exons or the last.
(C) Summary of clinical parameters for each tumor
group. In addition to summarized patient charac-
teristics, histological grade by Fuhrman score
and clinical stage by the American Joint Commit-
tee on Cancer Tumor Node Metastasis (TNM) sys-
tem are shown. Tumors scored as T1 or T2 (con-
fined to the kidney) were considered low stage,
while T3, T4, and M1 (invasive or metastatic
tumors) were considered advanced.H1H2 and H2 tumors, although slightly increased HIF-2amRNA
levels were noted in H2 tumors (data not shown). The apparent
discrepancy between HIF-1a mRNA and protein expression in
H2 tumors can be explained by multiple mechanisms, including
mutant pVHL proteins that selectively promote HIF-1a degrada-
tion (Rathmell et al., 2004) and direct effects of HIF-2a on HIF-1a
mRNA translation (Raval et al., 2005). Finally, available clinical in-
formation was segregated by group, and no significant differ-
ences were observed between VHL WT, H1H2, and H2 tumors
in either grade or stage of disease at surgery, although VHL
WT tumors showed a trend toward more frequent metastasis
(Figure 1C).
HIF-a Expression Modulates Oncogene Activation
Based on results from cell culture models (Gordan et al., 2007a),
we hypothesized that H2 tumors would display evidence of
increased c-Myc activity. Indeed, expression of the c-Myc-
activated targets cyclin D2 and E2F1 was 2- to 3-fold higher in
H2 tumors than in H1H2 or VHL WT tumors when measured by
qRT-PCR (Figure 2A). Similarly, the c-Myc-repressed targets
p21 and p27 were decreased in H2 tumors (Figure 2B). To rule
out alterations in overall c-Myc expression levels as an explana-
tion for these results, c-mycmRNA and protein abundance were
measured, and no consistent difference was found between
groups (Figure 2A and data not shown), nor were significant
c-myc amplifications detectedwith qPCR (Table S1). Ki-67 stain-
ing was performed to quantify cell proliferation (Figure 2C), and
a 55% increase in Ki-67+ nuclei was observed in H2 relative to
H1H2 tumors (Figure 2D). The clearest difference was between
low-stage tumors, which displayed approximately 60% more
Ki-67+ nuclei in H2 tumors than in VHL WT or H1H2 tumors,
although the analysis of high-stage tumors was limited by the
smaller number in this sample set (Figure 2D). Overall, these
data support our hypothesis that HIF-2a activation of c-Myc oc-
curs in human tumor specimens and correlates with increased
tumor cell proliferation. Although HIF-2a is expressed in H1H2
tumors, our previous data show that HIF-1a-mediated c-Myc in-Chibition directly opposes HIF-2a-mediated c-Myc activation
(Gordan et al., 2007a). Consistent with these data, H1H2 tumors
displayed levels of c-Myc target gene expression similar to those
in VHLWT tumors.
To extend these analyses in an unbiased manner, mRNA ex-
pression profiling was performed to identify global transcrip-
tional effects of differential HIF-a expression. VHL WT tumors
were included, both as a comparison group and to identify
unique markers of ccRCCs lacking HIF-a expression. Five
VHL WT, eight H1H2, and eight H2 tumors were analyzed.
These tumors were selected to represent a similar range of early
and advanced lesions in each group, and for optimal RNA qual-
ity. Comparisons were performed between VHL WT and VHL-
deficient tumors and between H1H2 and H2 tumors, identifying
a large number of differentially expressed genes (Table S2),
a subset of which are discussed further here. These compari-
sons revealed that H2 tumors expressed elevated levels of ad-
ditional c-Myc-responsive transcripts involved in the G1/S
phase cell-cycle transition (Coller et al., 2000; O’Connell et al.,
2003), including Skp2, Cdc7, CDT2, and dihydrofolate reduc-
tase (DHFR) (Figure 2E; Table S2). In contrast, VHL WT and
H1H2 tumors expressed lower but relatively similar levels of
these targets, as discussed above. IHC for Skp2 (Figures S2A
and S2B) and immunoblotting for Skp2 and Cdc7 (Figure S2C)
confirmed that changes in mRNA levels were reflected in protein
expression. The c-Myc antagonist Mxi was upregulated in VHL-
deficient tumors (Corn et al., 2005; Zhang et al., 2007), consis-
tent with decreased expression of c-Myc-regulated mitochon-
drial enzyme gene expression relative to VHLWT tumors (Table
S2). However, Mxi appeared to have limited impact on other
c-Myc targets, as c-Myc-regulated cell-cycle genes were in-
duced in H2 tumors but not VHL WT tumors despite increased
Mxi expression.
In striking contrast to c-Myc activation in H2 tumors, H1H2 tu-
morsdisplayed increasedmRNA levels of the genes encoding the
growth factor signalingmolecules Akt2 andRhoC, aswell as ribo-
somal L, S, and P proteins and the rRNA transcriptional regulatorancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc. 437
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expressed at higher levels in VHLWT tumors relative to H2 sam-
ples (Figure 3A). Intriguingly, we also noted increased expression
of genes encoding cytoskeletal proteins in VHLWT and H1H2 tu-
mors,which may be a result of enhanced growth factor signaling,
given the impact of growth factor-responsive proteins such as
RhoCon cell motility. These changes inmRNA levels could repre-
sent an adaptive mechanism in H1H2 tumors, as VHL loss is as-
sociatedwithdecreasedmatrix deposition and lossof cell polarity
(KimandKaelin, 2004). Toassessgrowth factor signalingmoredi-
rectly, we performed IHC for phosphorylated extracellular regu-
lated kinase (ERK, also referred to as mitogen-activated protein
kinase 1, or MAPK1) and ribosomal protein S6, a target of the
mTOR substrate p70 S6 kinase (Figure 3B). These proteins are
critical signaling molecules whose phosphorylation is induced
by multiple growth factor signal transduction pathways. In-
creased phospho-S6 and phospho-ERK staining was observed
in VHL WT and H1H2 compared to H2 tumors (p < 0.05 for
H1H2 versus H2; Figure 3C). In H2 tumors, detectable phospho-
S6 immunostaining was not observed in tumor cells but rather
was restricted to stromal cells associated with blood vessels
(Figure 3B, red arrowheads). These findings define a functional
distinction between ccRCC subsets: whereas c-Myc appears to
drive proliferation in H2 tumors, VHLWT and H1H2 tumors utilize
growth factor signaling pathways acting on ERK and S6.
As expected, the expression profiling experiments also re-
vealed increased expression of genes encoding multiple shared
HIF-1a and HIF-2a targets (vascular endothelial growth factor,
adrenomedullin, etc.) in all VHL-deficient tumors. Similarly,
Figure 2. Upregulation of c-Myc Cell-Cycle Targets
and Proliferation in H2 Tumors
(A) Expression of c-myc and c-Myc-activated targets as mea-
sured by qRT-PCR. Data for cyclin D2 (CCD2), E2F1, and
c-myc in VHL WT (n = 5), H1H2 (n = 8), and H2 (n = 8) tumors
are shown as fold change relative to pooled normal renal epi-
thelium, ±1 SEM. c-myc expression was tested with two inde-
pendent primer sets, as it showed a trend toward upregulation
(false discovery rate [FDR] = 0.2) in VHL-deficient versus VHL
WT tumors by microarray analysis. c-myc expression was
highly variable within tumor groups and was not found to be
significant by qRT-PCR (p > 0.25).
(B) Expression of the c-Myc-repressed targets p21 and p27,
shown as in (A).
(C) Representative Ki-67 staining in fresh-frozen tumors,
with positive nuclei indicated by red arrowheads. Scale
bar = 0.5 mm.
(D) Summary of Ki-67 staining from stages 1 and 2 (n = 4 VHL
WT, n = 9 H1H2, n = 8 H2), stages 3 and 4 (n = 2 VHLWT, n = 3
H1H2, n = 3 H2), or both combined. Data are shown as mean
percentage of Ki-67-positive cells, ± 1 SEM.
(E) Expression of the c-Myc-activated targets and G1/S tran-
sition mediators Skp2, CDC7, CDT2, and DHFR, analyzed as
in (A).
*p < 0.05, **p < 0.01.
H1H2 tumors (but not H2 tumors) expressed ele-
vated levels of HIF-1a-specific target genes, such
as those encoding glycolytic enzymes (Hu et al.,
2003) (Table S2). When two-way clustering was
performed on the microarray data, tumors largely
segregated into the same groups defined prospectively by
HIF-a expression (Figure 3D). Gene ontology analysis (Ficenec
et al., 2003) also identified classes of differentially expressed
genes in addition to those discussed here (Figure 3D). Thus,
the key features of each tumor subtype were consistently ob-
served within groups, with activation of c-Myc targets detected
exclusively in H2 tumors, in contrast to upregulated growth fac-
tor signaling components in VHL WT and H1H2 tumors.
HIF-2a Limits DNA Damage Accumulation
DNA damage from replication stress is commonly observed in
hyperproliferative tumor cells and can trigger a signaling path-
way including ATR, ATM, phospho-Chk1, phospho-Chk2, and
phosphohistone H2AX (gH2AX) (Bartkova et al., 2005; Gorgoulis
et al., 2005), potentially resulting in cell-cycle checkpoint activa-
tion. The ability to repair DNA damage through homologous re-
combination (HR) and nonhomologous end-joining (NHEJ) over-
comes these responses and promotes cellular proliferation. In
our expression profiling studies, we observed enhanced expres-
sion of genes encoding the HR effectors BRCA1, BARD1, and
XRCC2, as well as those encoding the spindle assembly check-
point proteins BUB1 andCENPE, in H2 tumors compared to VHL
WT and H1H2 tumors (Table S2). We confirmed these findings
with qRT-PCR (Figure 4A). Immunofluorescence for gH2AX
and Ki-67 revealed that H2 tumors contained 50% fewer strongly
gH2AX+ nuclei than VHLWT or H1H2 tumors, with a clear differ-
ence in gH2AX+/Ki-67+ nuclei (H2 tumors < 20% of VHL WT or
H1H2) (Figures 4B and 4C). Phospho-Chk2 staining also corre-
lated to gH2AX staining patterns (Figure 4D). The dramatic438 Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc.
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gests that they accumulate less DNA damage during replication.
DNA damage was directly measured by assessing the percent-
age of the genome that was aberrant (amplified or deleted) in
10 H1H2 and 11 H2 tumors by array-based copy number
analysis. Of note, a statistically significant 40% reduction was
noted in H2 tumors (Figure 4E).
Asour expressiondata implicatedHReffectors inDNAdamage
responses in H2 tumors, we assessed protein abundance and
function by immunofluorescence. When tumor sections were
stained for BARD1, expression was detected at homogeneous
levelswithin each section, but differenceswere noted in the num-
ber of foci between tumors (Figure 5A). There was a statistically
significant increase in the number of H2 tumors with moderate
to high numbers of BARD1 foci (defined as 15–30 and >30 foci
per nucleus, respectively) compared to H1H2 tumors. This differ-
ence was also significant when H2 tumors were compared to
H1H2 and VHL WT tumors grouped together (Figure 5B).
Whereas BARD1 staining tended to be homogeneous within tu-
mor sections, BRCA1 staining (Figure 5C) was more variable be-
tween nuclei for a given tumor. BRCA1 was present in a higher
proportion of all nuclei in H2 tumors, including those that were
gH2AX+ (Figure 5D), suggesting that HR activity reduces the
accumulation of stalled and collapsed replication forks in H2
tumors.
Figure 3. Microarray Analysis Defines
Separable Phenotypes in VHL WT, H1H2,
and H2 Tumors
(A) Genes associated with growth factor signaling
and protein translation significantly upregulated in
VHL WT and H1H2 tumors relative to H2 tumors.
Statistical significance was measured by FDR,
and fold differences relative to H2 are shown.
Gene names shown in bold were confirmed by
qRT-PCR in VHL WT (n = 5), H1H2 (n = 8), and
H2 (n = 8) tumors. Results for genes encoding
eIF3 and ribosomal protein (rp) L, S, and P sub-
units are the average of those shown.
(B) Representative immunohistochemistry (IHC)
for phospho-S6 and phospho-ERK in fresh-frozen
VHL WT, H1H2, and H2 tumors. Red arrowheads
indicate blood vessels. Scale bar = 5 mm.
(C) Summary of phospho-S6 and phospho-ERK
levels in VHL WT, H1H2 and H2 tumors, scored
asweak, intermediate, or strongbased on intensity
of staining. n=5, 12, and11, respectively. *p<0.05.
(D) Two-way complete linkage clustering of signif-
icantly altered genes between each subgroup
identifies both tumors and genes that show similar
patterns of expression. Tumor subtypes are identi-
fied by color, with VHL WT highlighted in green,
H1H2 in blue, and H2 in red. Red indicates higher
levels of expression. The gene set involved in cell
cycle and DNA damage responses is highlighted,
as this group was selected for further study.
To test the role of HIF-a subunits in HR
effector expression directly, we em-
ployed a VHL mutant ccRCC cell line
(RCC4) that expresses both HIF-1a and
HIF-2a. Vector-transduced control cells
were compared to HIF-1a knockdown (H1KD) cells (‘‘H1KD.1’’
and ‘‘H1KD.2’’) or HIF-2a knockdown (H2KD) cells (‘‘H2KD.1’’
and ‘‘H2KD.2’’) (Figure 6A; Figure S3A). Expression of a common
HIF-1a and HIF-2a target gene (VEGF), a HIF-1a-specific target
gene (PGK), and a HIF-2a-specific target gene (Oct-4) (Covello
et al., 2006; Hu et al., 2003) was assessed to confirm functional
HIF-a knockdown in these cells (Figure S3B). H1KD cells retain
HIF-2a activity and displayed enhanced c-Myc activity with ele-
vated cyclin D2 and E2F1 expression and decreased p21 and
p27 expression. In contrast, decreased c-Myc activity was ob-
served in H2KD cells, which retain HIF-1a expression
(Figure 6B). Similarly, HIF-1a knockdown promoted S phase en-
try, enhancing proliferation, whereas HIF-2a knockdown caused
accumulation in G1 and limited proliferation (Figures S3C and
S3D). Expression of other c-Myc targets, including Skp2,
CDC7, BARD1, and BRCA1, was found to be stimulated by
HIF-1a knockdown (Figure 6C) and inhibited by HIF-2a knock-
down, consistent with our observations using primary ccRCCs.
Although these mRNA changes are modest, they are likely to
have additive effects. In the caseofBRCA1, they also correspond
tomore dramatic changes in protein expression (Figure 6D). HIF-
1a and HIF-2a effects on BRCA1 and BARD1mRNA expression
werec-Mycdependent basedonsiRNAknockdownof c-Mycex-
pression (Figure 6E), consistent with previous studies showing
that c-Myc stimulates BRCA1 expression (Bindra et al., 2005;Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc. 439
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1a and HIF-2a in RCC4 cells canmodulate c-Myc activity, result-
ing in altered expression of HR mediators.
H1KD and H2KD cells were also evaluated for their response
to hydroxyurea (HU)-induced replication stress. HU blocks nu-
cleotide synthesis and inhibits DNA replication, resulting in rep-
lication fork stalling and ATR-mediated Chk1 phosphorylation.
Failure to resolve stalled replication forks leads to their collapse
and activation of ATM, Chk2, and p53, which can promote cell-
cycle arrest or senescence (Branzei and Foiani, 2007; Wang,
2007). Resolution of stalled forks requires HR, which is known
to occur in BRCA1 nuclear foci (Wang, 2007). HU-treated
H1KD (HIF-2a-expressing) cells displayed >50 BRCA1 foci per
nucleus, whereas <10 foci were detected in H2KD (HIF-1a-
expressing) cells. We also noted that H1KD cells exhibited less
dramatic gH2AX staining when compared to control or H2KD
cells (Figure 6F). In each case, BRCA1 and gH2AX foci displayed
overlapping nuclear distributions (Figure 6F). These data are
consistent with the large number of BRCA1 foci observed in
H2 tumors and suggest a specific role for HIF-2a in DNA damage
response in ccRCCs.
Functional consequences of differential DNA damage signal-
ing in HIF-a knockdown cells were examined. HU treatment of
cells synchronized in S phase induced rapid Chk1 phosphoryla-
Figure 4. H2 Tumors Exhibit Decreased Accumulation
of gH2AX and Genomic Aberrancy
(A) Enhanced expression of genes associated with homolo-
gous recombination (HR) and the spindle assembly check-
point in H2 tumors. Data from VHL WT (n = 5), H1H2 (n = 8),
and H2 (n = 8) tumors are shown as fold change relative to
pooled normal renal epithelium, ±1 SEM. *p < 0.05, **p < 0.01.
(B) Representative gH2AX/Ki-67 costaining in fresh-frozen
VHLWT, H1H2, and H2 tumors. DAPI was used to identify nu-
clei. Scale bar = 0.2 mm.
(C) Quantification of gH2AX staining in all cells and in Ki-67+
cells from VHL WT, H1H2, and H2 tumors (n = 6, 12, and 11,
respectively), ±1 SEM. **p < 0.01. Significant differences
also were observed for H1H2 and H2 between all nuclei and
Ki-67+ nuclei (p < 0.05).
(D) Characteristic phospho-Chk2/gH2AX costaining in repre-
sentative VHLWT, H1H2, and H2 tumors. Scale bar = 0.2 mm.
(E) Measurement of copy number by Illumina SNP arrays in
H1H2 and H2 tumors shows that a significantly lower percent-
age of the genome is aberrant in H2 tumors. *p < 0.04.
tion in all lines, suggesting equivalent activation of
the intra-S phase checkpoint (Figure 7A). In con-
trast, Chk2 phosphorylation and gH2AX were de-
creased in H1KD cells compared to control cells,
mirroring the differences observed between H2
and H1H2 tumor specimens (Figure 7A, left panel),
while the opposite result was observed in H2KD
cells (Figure 7A, right panel). Interestingly, H1KD
cells returned more rapidly to cell-cycle progres-
sion after HU treatment, whereas H2KD cells re-
covered more slowly (Figure 7B). These data sup-
port the notion that HIF-2a, in contrast to HIF-1a,
promotes more efficient HR-mediated repair and
resolution of replication stress, reducing the accu-
mulation of DNA damage and activation of checkpoint re-
sponses.
We used an independent experimental approach to evaluate
the effect of HIF-a expression on cell-cycle progression under
conditions of replication stress. Cells were incubated for 20 hr
in 1 mg/ml aphidicolin, a concentration at which aphidicolin re-
duces DNA polymerase progression through complex genomic
structures and can activate an intra-S phase checkpoint charac-
terized by cells with hyperdiploid DNA content (>2N). In RCC4
cells, HIF-1a knockdown promoted successful completion of
S phase as indicated by a significant decrease in the proportion
of >2N cells compared to control lines (Figure 7C), consistent
with the hypothesis that these cells respond more effectively to
DNA replication stress. In contrast, H2KD cells showed a trend
toward failure to complete S phase (p = 0.06). Interestingly, cells
completingG1 in the presence of low-dose aphidicolin treatment
are capable of firing early origins of replication and incorporating
bromodeoxyuridine (BrdU), although DNA synthesis at newly
fired origins is severely diminished (Dimitrova and Gilbert,
2000); consequently, these cells appear as BrdU positive with
2N DNA content (2N/BrdU+). H1KD and H2KD cells were treated
with aphidicolin as described above and then pulsed with BrdU
for 20 min to label newly fired origins in cells that had success-
fully completed G1. H1KD cells showed a significantly higher440 Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc.
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2N/BrdU+ cells, whereas H2KD cells showed significantly lower
rates (Figure 7C). In summary, HIF-2a expression (in the ab-
sence of HIF-1a) was correlated with increased BRCA1 expres-
sion and efficient S phase completion, thereby permitting cell-
cycle progression in the face of replication stress while limiting
phospho-Chk2 and gH2AX accumulation. Conversely, HIF-1a
expression was associated with elevated markers of DNA dam-
age and a limited ability to proliferate when challenged with rep-
lication stress, in keeping with the model presented in Figure 7D.
Importantly, results from these functional in vitro studies using
replication stress mimetics are consistent with our observations
of DNA stress markers in ccRCC tumors.
Validation of Expression and Signaling Changes
in Additional Tumor Samples
Having identified HIF-a-intrinsic effects on cell-cycle and DNA
repair pathways in human tumor specimens, we sought to con-
firm them in two independent sets of patient samples.Microarray
analysis was performed on a second group of 12 ccRCCs, col-
lected at the University of North Carolina. All tumors were scored
as VHL deficient because they showed strong HIF-a staining in
>75% of cells, significant upregulation of multiple HIF targets,
and decreased VHL expression compared to controls. Samples
were separated into H1H2 and H2 subgroups (n = 7 and 5, re-
spectively), and differentially expressed genes were analyzed.
As described above, tumors clustered by HIF-a expression (Fig-
ure S4A), exhibiting gene expression consistent with increased
glycolytic metabolism and growth factor signaling in H1H2 tu-
mors and enhanced cell-cycle progression and HR gene expres-
sion in H2 tumors. Comparing these results to our primary anal-
ysis, we observed a 30%–40% concordance between the data
sets (p < 13 1012), commensurate with published reports com-
paring arrays performed under similar conditions (Subramanian
Figure 5. H2 Tumors Show Enhanced Signs of HR-
Mediated Repair
(A) Representative BARD1 staining with DAPI to indicate nu-
clei in VHL WT, H1H2, and H2 tumors. Scale bar = 0.1 mm.
(B) Quantification of BARD1 nuclear staining in VHLWT (n = 4),
H1H2 (n = 11), and H2 (n = 12) tumors. Weak staining was
scored as 0–15 foci/nucleus, intermediate as 15–30, and
strong as >30.
(C) Representative BRCA1/gH2AX costaining in VHL WT,
H1H2, and H2 tumors. Scale bar = 0.1 mm.
(D) Quantification of BRCA1 foci in gH2AX+ nuclei from VHL
WT, H1H2, and H2 tumors, ±1 SEM.
*p < 0.05, **p < 0.01.
et al., 2005). Ki-67 staining (Figure S4B) was also
consistent with data from our initial tumor set.
Genes exhibiting increased expression in all H2
tumors are listed in Figure S3C and include those
encoding cyclin D2, E2F1, Skp2, DHFR, BARD1,
and BRCA1.
To confirm the biological phenotypes described
above and to analyze a data set with information re-
garding clinical outcome, IHC was performed on
a tissuemicroarray (TMA) containing triplicate sam-
ples from 93 randomly selected ccRCCs from the University of
Pennsylvania. TMA slides were immunostained for HIF-1a and
HIF-2a proteins (Figure 8A), and a similar distribution of the three
groups was observed (Figure 8B). Tumors were categorized as
VHL WT if neither HIF-1a nor HIF-2a staining was observed.
The tumors in this data set tended to be of lower stage than
the initial group, but a similar proportion were metastatic at pre-
sentation. Metastatic relapse was observed in H1H2 and H2 tu-
mors over amedian 6 years of follow up, with comparable overall
rates between groups (Figure 8B). Notably, H2 tumors were sig-
nificantly larger in volume compared to VHLWT or H1H2 tumors
(Figure 8B; p < 0.008 and 0.04, respectively). Ki-67, phospho-S6,
and gH2AX staining was performed, and H2 tumors displayed
60% more Ki-67+ cells relative to H1H2 and VHL WT tumors
(Figure 8C), whereas phospho-S6 (Figures 8D and 8E) and
gH2AX (Figures 8F and 8G) staining was significantly higher in
both VHLWT and H1H2 compared to H2 tumors. These data ex-
tended our analysis of HIF-a effects to advanced tumors, which
had not previously been possible in the smaller initial tumor col-
lection. These two data sets (105 additional samples) confirm
and extend the phenotypic characterization of the initial ccRCC
subgroups (Figure 1), as well as the increased expression of spe-
cific gene targets in H2 tumors (Table S2) associated with in-
creased cell-cycle progression and HR.
DISCUSSION
Human ccRCCs are typically subdivided into two distinct groups
based on VHL status. Approximately 70% of sporadic ccRCCs
have lost pVHL expression through VHL deletion and/or silenc-
ing (Banks et al., 2006; Kim and Kaelin, 2004), but additional
criteria by which pVHL-deficient tumors can be classified have
not been described. Here, we demonstrate that VHL-deficient
ccRCCs can be distinguished on the basis of differential HIF-aCancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc. 441
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Enhanced HR Effector Expression
(A) HIF-1a and HIF-2a expression in control and
knockdown cell lines. ‘‘H1KD.1’’ and ‘‘H1KD.2’’
exhibit HIF-1a knockdown, and ‘‘H2KD.1’’ and
‘‘H2KD.2’’ exhibit HIF-2a knockdown. Actin is
shown as a loading control. See Figure S1A for
changes in HIF-1a and HIF-2a mRNA levels in
control and knockdown cells.
(B) Differential expression of c-Myc-repressed
(p21 and p27) and c-Myc-activated (cyclin D2
and E2F1) targets in control and knockdown cell
lines. Average values from four experiments are
shown, ±1 SEM.
(C) Expression of G1/S phase cell-cycle targets
and HR genes in knockdown cell lines, analyzed
as in (B).
(D) Western blot analysis of BRCA1 and BARD1 in
control and knockdown cell lines; actin is shown
as a loading control.
(E) qRT-PCR for expression of c-myc,BRCA1, and
BARD1 in control and HIF-1a knockdown RCC4
clones transfected with control siRNA or two dif-
ferent siRNAs against c-Myc. Average values
from three experiments are shown, ±1 SEM.
(F) Representative images of BRCA1/gH2AX
costaining in control (Ctl1) and HIF-a knockdown
cell lines after 3 hr treatment with 1.5 mM hydroxy-
urea (HU). Results from one control line are shown,
as both produced equivalent results. Scale
bar = 0.2 mm.expression and consequent HIF-dependent effects on c-Myc
activity. Specifically, we found that H2 tumors displayed en-
hanced c-Myc activity, higher rates of proliferation, increased
volume, and lower levels of gH2AX accumulation than H1H2 or
VHL WT tumors. In contrast, H1H2 and VHL WT tumors dis-
played increased activation of Akt/mTOR and ERK/MAPK1
growth factor signaling pathways and enhanced gH2AX accu-
mulation. Although VHL WT and H1H2 tumors generally share
these traits, prior work (Turner et al., 2002) and our expression
profiling data strongly suggest that H1H2 tumors are more an-
giogenic than VHL WT tumors. This study presents evidence of
differential HIF/c-Myc effects in patient-derived tumor samples
and describes a previously unappreciated interplay between
HIF-2a, c-Myc, and genome stability. Together, these data pro-
vide a mechanistic basis on which to subdivide ccRCCs for
molecularly targeted therapy.
The in vitro and in vivo findings presented here extend HIF-2a/
c-Myc cell-cycle effects to include promotion of efficient transit
through S phase by stimulating expression of HR mediators, as
well as genes encoding proteins that limit replication stress by
enhancing nucleotide pools (DHFR) (Milbrandt et al., 1981) or
blocking rereplication (Skp2 and Cdt2) (Nishitani et al., 2006).
As HIF-1a and HIF-2a have opposite effects on c-Myc, our find-
ings are consistent with previous observations that HIF-1a in-
hibits mismatch repair by blocking c-Myc activity (Koshiji
et al., 2005). It should be noted, however, that hypoxia directly
promotes genomic instability in a HIF-1a-independent fashion
(Bristow and Hill, 2008). Thus, tumors expressing only HIF-2a
may be able to compensate for hypoxia-induced genomic insta-
bility. Intriguingly, our findings suggest that Mxi upregulation by
HIF-1a and HIF-2a (Zhang et al., 2007) exerts a specific effect
on mitochondrial metabolism without impacting several other
c-Myc-driven processes. These results delineate the in vivo im-
pact of HIF/c-Myc effects in ccRCC and highlight contrasting
properties of HIF-1a and HIF-2a in c-Myc-regulated DNA dam-
age repair.
The decreased levels of gH2AX and increased numbers of
Ki-67+ nuclei observed in H2 tumors reveal a correlation between
enhanced proliferation and decreased levels of DNA damage.
Given the concomitant upregulation of the HR effectors
BRCA1 and BARD1, these findings implicate enhanced resolu-
tion of replication stress as a mechanism by which tumor cells
escape the cell-cycle block imposed by DNA damage-activated
checkpoints. The fact that HIF-2a-expressing RCC4 cells, which
display enhanced BRCA1 and BARD1 expression, recover more
rapidly from HU and aphidicolin further supports the hypothesis
that enhanced HR contributes to tumor cell proliferation in the
context of replication stress. Similarly, a key role for HR in normal
cell-cycle progression has been suggested by targetedmutation
of murine Brca1 and Bard1, as disruption of either gene dramat-
ically limits proliferation in embryonic cells (McCarthy et al.,
2003; Xu et al., 1999). Differing levels of replication stress could
underlie the variable activation of DNA damage response ma-
chinery observed in different tumor types. For example, whereas442 Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc.
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with Resistance to Replication Stress
(A) Western blot analysis of Chk1, Chk2, and
gH2AX phosphorylation following 1.5 mM HU
treatment of control and HIF-a knockdown cell
lines synchronized in S phase by timed release
from serum withdrawal and confluency. Total
Chk1, Chk2, H2AX, and actin are shown as
controls.
(B) Return to DNA replication following 1 hr treat-
ment of S phase-synchronized cells with 1.5 mM
HU, measured by BrdU incorporation. Average
percentage of BrdU+ cells are shown from three
experiments, ±1 SEM. Statistically significant dif-
ferences between Ctl1 and H1KD.1, Ctl2 and
H2KD.2, and H1KD.1 and H2KD.2 were assessed.
*p < 0.05.
(C) BrdU incorporation in cells grown for 20 hr in
the presence of 1 mg/ml aphidicolin. Percentage
of cells with >2N DNA content is shown, as is the
2N/BrdU+ percentage. Data are from one repre-
sentative experiment, ±1 SD. *p < 0.05, **p < 0.01.
(D) Simplified model outlining responses to repli-
cation stress. Various stress inducers have been
shown to activate ATR, leading to Chk1 phosphor-
ylation and DNA repair, with replication fork col-
lapse activating ATM, enhancing gH2AX accumu-
lation, and promoting cell-cycle exit. These data
are consistent with a model wherein HIF-2a pro-
motes the former pathway (highlighted in red)
and HIF-1a-expressing cells tend to exhibit the lat-
ter (highlighted in blue).tumors of the lung, bladder, and skin appear dependent on
stepwise dismantling of DNA damage responses for progres-
sion (Bartkova et al., 2005; Gorgoulis et al., 2005), recent studies
suggest that stomach, colorectal, and breast adenocarcinomas,
as well as testicular germ cell tumors, have minimal DNA dam-
age response activation at all stages (Bartkova et al., 2007;
Nuciforo et al., 2007). More efficient progression through S
phase has not been previously described as a pathway for en-
hanced tumor cell proliferation and is likely to be of particular
importance in early-stage tumor cells with intact DNA damage
checkpoints.
The combination of VHL genotype and HIF-a expression
allows the stratification of ccRCCs into biologically distinct
groups and suggests a framework for subclassifying tumors
for targeted therapies. Although several targeted drugs with dis-
tinct mechanisms of action are available to treat metastatic
ccRCC, there are currently no parameters to select the optimal
drug for each patient. Sunitinib and sorafenib each appear to in-
hibit tumor angiogenesis and tumor cell viability through their
effects on VEGF signaling in endothelial cells and, potentially,
tumor cells. These agents differ with respect to the potency of
their interactions with VEGF and PDGF receptors, most notably
with respect to the Raf/MAP kinase pathway, an exclusive tar-
get of sorafenib. We suggest that growth factor-driven ccRCCs
(VHL WT and H1H2) are more likely to respond to these drugs.
Similarly, while treatment with erlotinib (targeting the epidermal
growth factor receptor) and bevacizumab (inhibiting angiogene-
sis) confers no benefit as compared to bevacizumab alone inCunselected patients (Motzer and Bukowski, 2006), this combi-
nation might exclusively show increased efficacy against the
H1H2 subset. Furthermore, whereas the antiangiogenic effects
of sorafenib and sunitinib should impact the vasculature in H2
tumors, these tumors are nevertheless likely to progress, as
HIF-2a-dependent c-Myc activation could promote growth in
relatively well-oxygenated tumor subdomains. Expression of
HIF-2a alone may therefore mark a subset of RCCs that are
uniquely resistant to the current targeted therapeutics. While
retrospective and prospective studies are needed to demon-
strate a connection between HIF-a expression and therapeutic
response, HIF-a analysis enables us to stratify ccRCC patients
and thus examine predictors of outcome based on biological
differences in clinical trials of targeted therapies.
EXPERIMENTAL PROCEDURES
Patient Material
Frozen material for primary analysis was obtained through the Collaborative
Human Tissue Network. OCT-embedded blocks were sectioned until cut
planes were >70% tumor. Sections were collected for DNA, RNA, and protein
extraction. Material for tissue microarray (TMA) analysis was obtained from ar-
chival specimens at the University of Pennsylvania. Both protocols were ap-
proved by the University of Pennsylvania Institutional Review Board. Samples
were cataloged, clinical information on cases was obtained through chart re-
view, and patient identifiers were removed before analysis. Material for micro-
array validation was collected at the University of North Carolina from surger-
ies performed on site. Approval was given by the University of North Carolina
Institutional Review Board.ancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc. 443
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DNA was extracted from tumor samples using an EX-WAX DNA extraction kit
(Chemicon). Mutation screening was performed on PCR-amplified exons by
direct sequencing with a BigDye Terminator Cycle kit on a 3130xl sequencer
(Applied Biosystems). Primers and protocols were used as described previ-
ously (Stolle et al., 1998). Methylation studies were performed using a CpG
Wiz kit (Chemicon) and/or NotI digestion (Herman et al., 1994).
Immunohistochemistry
For frozen specimens, 10 mm sections were fixed with 4% paraformaldehyde,
permeabilized with PBS/0.5% Triton X-100, and stained following standard
protocols detailed further in Supplemental Experimental Procedures. For
HIF-a staining, slides were scored as positive if more than 40% of nuclei
stained positive. Cytoplasmic staining was not considered. For Ki-67, Skp2,
gH2AX, phospho-Chk2, and BRCA1, 3–4 high-power images were counted
for percentage positive and then averaged to give a mean rate per tumor, ex-
cept for Ki-67 on TMA cores, where the entire core was counted in each case.
Only cells with clear tumor cell morphology were scored. For phospho-ERK,
phospho-S6, and BARD1, samples were scored as negative/weak, intermedi-
ate, or strong. For these and for HIF-a staining, analysis was performed by
multiple investigators, including J.D.G., P.L., and K.N.P.
TMA Design and Production
Ninety-four ccRCC sampleswere selected from tissue archives at University of
Pennsylvania, representing ninety-three primary tumors and one metastasis.
Hematoxylin and eosin-stained sections were evaluated to confirm the initial
diagnosis, and three 0.6 mm tissue cores were selected from different areas
of each tumor. Matched normal renal epithelium was included for 2/3 of cases,
Figure 8. Tissue Microarray Analysis of
Biological Parameters and Patient Outcome
(A) Representative HIF-1a and HIF-2a staining
from paraffin-embedded tissue microarray (TMA)
cores. Scale bar = 2 mm.
(B) Summary of patient information and clinical
outcomes across IHC-determined groups. Vol-
ume is shown in cm3. *p < 0.05.
(C) Summary of Ki-67 staining from low- and high-
stage tumors or both combined. Data are shown
as mean percentage of Ki-67-positive cells, ±1
SEM. *p < 0.05, **p < 0.01.
(D) Representative phospho-S6 staining. The VHL
WT and H1H2 sections shown were scored as in-
termediate and the H2 section as negative, though
endothelial cell phospho-S6 can be noted (red ar-
rowheads). Scale bar = 0.5 mm.
(E) Summary of phospho-S6 staining in VHL WT,
H1H2, and H2 tumors. *p < 0.05, **p < 0.01.
(F) Representative gH2AX shown with DAB and
fluorescent staining. Middle row also shows
DAPI so that negative nuclei can be discerned,
whereas bottom row shows only gH2AX. Scale
bars = 2 mm (top), 0.5 mm (middle), and 0.2 mm
(bottom).
(G) Quantification of fluorescent gH2AX staining in
all tumors, ±1 SEM. *p < 0.05, **p < 0.01.
and renal angiomyolipomas and spleen cores
were also included as staining controls. Cores
were assembled and cut into sections as de-
scribed previously (Kononen et al., 1998).
Microarrays
Primary expression microarray analysis was per-
formed at the University of Pennsylvania Microar-
ray Core using the Affymetrix U133 Plus 2.0 array,
with analysis using GenePattern (Broad Institute of MIT and Harvard) (Reich
et al., 2006). Array-based comparative genomic hybridization was also per-
formed at the University of Pennsylvania Microarray Core using the Illumina
550K-2 v3.1 array and analyzed using Partek Genomics Suite, while the valida-
tion set of expression arrays was hybridized at the University of North Carolina
Genomics Core using the Agilent 4x44K array format, with a standard refer-
ence RNA used in the second channel and analyzed with statistical analysis
of microarrays. Analytical methods are described in Supplemental Experimen-
tal Procedures.
Statistical Analysis
Significance was typically evaluated by two-tailed Student’s t test. When
t tests were performed on data from multiple measurements (e.g., counting
four images of one slide), values were averaged by tumor before inclusion
in the test. For noncontinuous measurements, Fisher’s exact test was used
with 2 3 2 tables, except for phospho-S6 and phospho-ERK staining, where
2 3 3 and 3 3 3 chi-square tables were used.
Cell Culture, Drug Treatments, and Synchronization
RCC4 cells were cultured in DMEM with 10% FCS (Gemini), standard
additives, and 1 mg/ml puromycin. Knockdown clones were generated by
retroviral transduction using pBABE HIF-1a shRNA (Lum et al., 2007) and
pRETROSUPER HIF-2a shRNA (Kondo et al., 2003) (generous gift of W.G.
Kaelin, Dana-Farber Cancer, Boston). Hydroxyurea (Sigma) was prepared in
water and used at 1.5 mM. Aphidicolin was prepared in DMSO and used at
1 mg/ml. Cells were synchronized in G1 by confluency and serum withdrawal
for 24 hr and released by trypsinization and replating. H1KD, control, and
H2KD cell lines were released 18, 20, and 22 hr before HU treatment, respec-
tively, ensuring that 50%–60% of cells were in S phase and the remainder in444 Cancer Cell 14, 435–446, December 9, 2008 ª2008 Elsevier Inc.
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Procedures.
ACCESSION NUMBERS
The raw data for expression profiling and single-nucleotide polymorphism
(SNP)-based copy number data are available through the NCBI Gene Expres-
sion Omnibus (GEO) at http://www.ncbi.nlm.nih.gov/geo/ with the accession
numbers GSE11904 and GSE11985 for expression profiling data (University
of Pennsylvania and University of North Carolina, respectively) and
GSE13282 for SNP-based copy number data.
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The Supplemental Data include Supplemental Experimental Procedures, four
figures, and two tables and can be found with this article online at http://www.
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